Professor Raanan Berger

Dr. Raanan Berger is an authoritative and sought-after specialist in urological oncology and urogenital oncopathology. Many years of clinical experience make him an excellent diagnostician able to recognize disease at the earliest stage, which is extremely valuable for precise antitumor intervention, and genuine clinical talent allows him to successfully carry out drug and radiological treatment of urogenital tumors with maximum effectiveness.

Raanan Berger studied medicine in Israel at the Sackler Faculty of Tel Aviv University, after which he continued to improve in genetics. After four years of graduate study he defended his dissertation on the specific differentiation-controlling gene Thymopoietin/LAP2, which helped him better understand how immune defense, including antitumor defense, forms in the human body. He then specialized in general oncology and radiotherapy at Chaim Sheba Medical Center, and trained in oncological urology and urogynecology at the Dana-Farber Cancer Institute, Harvard Medical School in Boston (USA), studying modern diagnosis and treatment of prostate cancer. Returning to Israel, Dr. Berger worked as a clinical resident in the oncology and radiotherapy department at Sheba and later became head of this department, simultaneously heading the Gidi Rechavi Department of Clinical Research.

Today Dr. Raanan Berger works at Sheba and is a senior uro-oncologist at the private Assuta clinic. A brilliant physician and talented researcher, he is recognized as one of Israel's best specialists in radiological treatment of genitourinary cancers. Understanding the importance of finding promising approaches to cancer treatment and prevention, Dr. Berger conducts active research in this field: he is the creator and coordinator of a research group studying the action of new antitumor drugs, leads all three phases of clinical trials of the newest cancer drugs, and heads a medical laboratory whose specialists study the biological mechanisms of prostate cancer and are building its genetic model, which will help open ways to fight hereditary prostate cancer effectively. Dr. Berger teaches oncology at the Faculty of Medicine of Tel Aviv University, is the author of several dozen scientific papers on cancer genetics and uro-oncology, and belongs to a number of European and Israeli professional societies.

Dr. Raanan Berger treats a wide range of oncological diseases of the urogenital sphere, including surgical and radiological treatment of:

• prostate and testicular cancer;
• kidney cancer;
• bladder and ureteral cancer.

Every year he sees more than 500 patients, for whom he conducts comprehensive and targeted cancer diagnostics, radiation and drug (chemotherapy) treatment, targeted (narrowly focused on the tumor) and biological treatment, brachytherapy (contact radiotherapy with minimized complications), and clinical trials of new antitumor drugs.